OLMA Olema Pharmaceuticals Inc

Price (delayed)

$12.3

Market cap

$687.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.01

Enterprise value

$656.48M

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is ...

Highlights
OLMA's EPS is up by 27% YoY and by 6% QoQ
The debt has declined by 9% since the previous quarter and by 3.6% year-on-year
Olema Pharmaceuticals's equity has increased by 35% YoY but it has decreased by 7% from the previous quarter
Olema Pharmaceuticals's net income has increased by 10% YoY but it has decreased by 2.8% from the previous quarter
OLMA's quick ratio is down by 22% since the previous quarter

Key stats

What are the main financial stats of OLMA
Market
Shares outstanding
55.93M
Market cap
$687.99M
Enterprise value
$656.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$99.34M
EBITDA
-$97.72M
Free cash flow
-$86.97M
Per share
EPS
-$2.01
Free cash flow per share
-$1.56
Book value per share
$4.23
Revenue per share
$0
TBVPS
$4.74
Balance sheet
Total assets
$263.69M
Total liabilities
$27.38M
Debt
$2.21M
Equity
$236.32M
Working capital
$225.87M
Liquidity
Debt to equity
0.01
Current ratio
9.61
Quick ratio
9.49
Net debt/EBITDA
0.32
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-39.3%
Return on equity
-42.9%
Return on invested capital
-57.8%
Return on capital employed
-41.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OLMA stock price

How has the Olema Pharmaceuticals stock price performed over time
Intraday
-1.6%
1 week
15.28%
1 month
-4.43%
1 year
37.58%
YTD
-12.33%
QTD
13.68%

Financial performance

How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.7M
Net income
-$99.34M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has increased by 10% YoY but it has decreased by 2.8% from the previous quarter
The operating income has decreased by 4.5% QoQ but it has increased by 3.2% YoY

Growth

What is Olema Pharmaceuticals's growth rate over time

Valuation

What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 27% YoY and by 6% QoQ
Olema Pharmaceuticals's equity has increased by 35% YoY but it has decreased by 7% from the previous quarter
OLMA's price to book (P/B) is 16% more than its last 4 quarters average of 2.5

Efficiency

How efficient is Olema Pharmaceuticals business performance
Olema Pharmaceuticals's ROE has increased by 20% YoY and by 4% from the previous quarter
The return on assets has grown by 20% year-on-year and by 4.1% since the previous quarter
The return on invested capital has grown by 8% since the previous quarter and by 4.5% year-on-year

Dividends

What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OLMA.

Financial health

How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total assets has increased by 35% YoY but it has decreased by 4.8% from the previous quarter
Olema Pharmaceuticals's total liabilities has increased by 32% YoY and by 19% from the previous quarter
The debt is 99% smaller than the equity
Olema Pharmaceuticals's equity has increased by 35% YoY but it has decreased by 7% from the previous quarter
The debt has declined by 9% since the previous quarter and by 3.6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.